Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Carmen Magistro

Physician Assistant, Medical Bellevue, NE Physician Assistant

NPI 1841258563 CMS profile 10646971

2206 Longo Dr Ste 201, Bellevue, NE 68005

Open in the dashboard

General payments

$7,820

515 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carmen Magistro of Bellevue, NE is reported in the CMS Open Payments database as having received $7,820 across 515 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,181 63
2024 General $1,879 109
2023 General $1,412 81
2022 General $1,459 114
2021 General $1,889 148

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carmen Magistro
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Carmen Magistro were reported at $1,181. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Carmen Magistro Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,889 $156 $41–$563 $132
2022 $1,459 $185 $55–$649 $149
2023 $1,412 $199 $58–$717 $160
2024 $1,879 $206 $62–$740 $164
2025 $1,181 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,165 79 payments
  2. Novo Nordisk Inc $914 71 payments
  3. Lilly USA, LLC $864 71 payments
  4. AstraZeneca Pharmaceuticals LP $748 30 payments
  5. Antares Pharma, Inc. $417 51 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $327 24 payments
  7. Amgen Inc. $312 23 payments
  8. Pfizer Inc. $301 17 payments
  9. ITI, Inc. $246 2 payments
  10. Janssen Pharmaceuticals, Inc $181 11 payments
  11. Other $2,345 136 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,813 513 payments
  2. Education $8 2 payments
Products named General payments · program years 2021–2025
  1. Ozempic $739 61 payments
  2. RYBELSUS $718 60 payments
  3. QULIPTA $612 34 payments
  4. MOUNJARO $586 42 payments
  5. UBRELVY $418 32 payments
  6. VRAYLAR $329 23 payments
  7. XIFAXAN $327 24 payments
  8. BREZTRI $259 7 payments
  9. ZEPBOUND $249 19 payments
  10. CAPLYTA $246 2 payments
  11. Other $5,662 395 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 98 drugs

Part D claims

3,797

Median for Physician Assistant: 241

Drug cost

$224,752

Median for Physician Assistant: $4,110

Branded share of claims

17.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 40 $61,275
Ozempic Semaglutide Brand 43 $40,832
Eliquis Apixaban Brand 39 $39,729
Jardiance Empagliflozin Brand 18 $15,489
Trulicity Dulaglutide Brand 12 $9,564
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 12 $7,636
Fenofibrate Generic 49 $2,404
Lisdexamfetamine Dimesylate Generic 12 $1,935
Testosterone Cypionate Generic 75 $1,881
Progesterone Progesterone, Micronized Brand 28 $1,863

The 10 drugs with the highest cost, of 98 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 86 billing codes

Paid by Medicare

$111,402

Of which drugs: $2,899

Medicare patients

336

Average age 73

Services billed

44,485

130 women, 206 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 40%
Diabetes 22%
Ischemic heart disease 21%
Atrial fibrillation 16%
Chronic kidney disease 12%
COPD 12%
Cancer 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 17 17 $1,306
Injection, testosterone cypionate, 1 mg J1071 Office 25 38,305 $689
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 22 625 $149
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 30 152 $102
Injection, ketorolac tromethamine, per 15 mg J1885 Office 31 174 $92
Injection, methylprednisolone acetate, 1 mg J1010 Office 14 606 $63
Injection, ceftriaxone sodium, per 250 mg J0696 Office 31 140 $48

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $156
$156 40 —
QULIPTA
  • AbbVie, Inc. $128
$128 — —
CAPLYTA
  • ITI, Inc. $121
$121 — —
ZEPBOUND
  • Lilly USA, LLC $112
$112 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $77
  • Lundbeck LLC $30
$106 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

515 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record